MedTrace Logo

Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers

NCT02254720 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2014-10-02

No results posted yet for this study

Summary

Evaluation of safety, tolerability and pharmacokinetics of single rising intravenous doses of BEA 2180 BR; additional exploration of metabolism following inhalation

Conditions

  • Healthy

Interventions

DRUG

BEA 2180 BR solution for infusion

DRUG

Placebo

Intravenous infusion

DRUG

BEA 2180 BR solution for inhalation

DEVICE

Respimat®

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2006-12-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02254720 on ClinicalTrials.gov